Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016069392) ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2016/069392 International Application No.: PCT/US2015/057062
Publication Date: 06.05.2016 International Filing Date: 23.10.2015
IPC:
C07D 487/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
Applicants:
MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 40 Landsdowne Street Cambridge, MA 02139, US
Inventors:
BENCE, Neil; US
HUCK, Jessica; US
HYER, Marc; US
MILHOLLEN, Michael; US
SHI, Judy, Qiuju; US
TRAORE, Tary; US
Agent:
LOU, Changgang; US
Priority Data:
62/072,31129.10.2014US
Title (EN) ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
(FR) ADMINISTRATION D'INHIBITEUR D'ENZYME ACTIVANT L'UBIQUITINE ET AGENTS CHIMIOTHÉRAPEUTIQUES
Abstract:
(EN) Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio)phenyl)pyrazolo [1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of cancer.
(FR) La présente invention concerne des méthodes de traitement d'un cancer chez des patients ayant besoin d'un tel traitement. Les procédés comprennent l'administration, à un tel patient, d'un inhibiteur de l'enzyme activant l'ubiquitine (UAE), tel que le sulfamate de ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluorométhylthio)phényl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)méthyle (Composé 1) ou un sel pharmaceutiquement acceptable, en combinaison avec un ou plusieurs agents chimiothérapeutiques. L'invention concerne également des médicaments destinés à être utilisés dans le traitement du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
JP2017533223US20180133221